This is a working overview of fatty acid oxidation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-09 and is reviewed periodically as new material appears.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Castor oil is still used for labor induction in environments where modern drugs are not available; a review of pharmacologic, mechanical, and "complementary" methods of labor induction published in 2024 by the American Journal of Obstetrics and Gynecology stated that castor oil's physiological effect is poorly understood but "given gastrointestinal symptomatology, a prostaglandin mediation has been suggested but not confirmed." According to Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (2008), castor oil should not be ingested or used topically by pre-term pregnant women. There is no data on the potential toxicity of castor oil for nursing mothers. There is no high-quality research proving that ingestion of castor oil results in cervical ripening or induction of labor; there is, however, evidence that taking it causes nausea, vomiting, and diarrhea. A systematic review of "three trials, involving 233 women, found there has not been enough research done to show the effects of castor oil on ripening the cervix or inducing labour or compare it to other methods of induction. The review found that all women who took castor oil by mouth felt nauseous. More research is needed into the effects of castor oil to induce labour."
=== Eugenics === Crick occasionally expressed his views on eugenics, usually in private letters. For example, Crick advocated a form of positive eugenics in which wealthy parents would be encouraged to have more children. He once remarked, "In the long run, it is unavoidable that society will begin to worry about the character of the next generation ... It is not a subject at the moment which we can tackle easily because people have so many religious beliefs and until we have a more uniform view of ourselves I think it would be risky to try and do anything in the way of eugenics ... I would be astonished if, in the next 100 or 200 years, society did not come round to the view that they would have to try to improve the next generation in some extent or one way or another."
In one recent study, of 83 men with undetectable viral loads, 21 had very slight but not undetectable viral loads in their semen. However, it is unclear how much this actually increases transmission risk.
People who receive atoltivimab/maftivimab/odesivimab should avoid the concurrent administration of a live vaccine due to the treatment's potential to inhibit replication of a live vaccine virus indicated for prevention of Ebola virus infection and possibly reduce the vaccine's efficacy. Atoltivimab/maftivimab/odesivimab is a combination of Zaire ebolavirus glycoprotein-directed human monoclonal antibodies. The three antibodies target the glycoprotein that is on the surface of the Ebola virus. This glycoprotein normally attaches to the cell via a receptor and fuses the viral and host cell membranes allowing the virus to enter the cell. The antibodies can bind to it simultaneously at three different locations and block attachment and entry of the virus. This combination drug targets the Zaire species of Ebola virus. The Sudan and Bundibugyo strains have also caused outbreaks, and it is unlikely that it would be effective against these strains.
Sources: en.wikipedia.org
== Development == Valve entered the VR space in the mid-2010s, demonstrating the Robot Repair VR demo at the 2015 Game Developers Conference. The following year, they partnered with HTC and released the HTC Vive, along with a series of "experiments" called The Lab. Plans to develop a new Half-Life game began after this, and Valve started a project named "The Prototype", helmed by Robin Walker. Concerned that other companies would limit the scope of VR technology, Walker felt that Valve had a duty as a game developer to get involved. Onboarding others in Hawaii opened up two more projects alongside the Index, those being the A.R.T.I. project and SimTrek. These plans ultimately fell through. Walker envisioned a controller that allowed for hand tracking, rather than just functioning as a remote control. The newly focused project developed a slimmed down headset and controllers, named the "Knuckles", that allowed for "believable" hands whilst in VR. Development kits for the Knuckles, codenamed "EV2", were showcased in 2018. Design elements, such as the large trackpad, were adapted from the HTC Vive controllers. These were later toned down, with a thumbstick implemented and a "track button", which is a tracking surface that sat between the stock and now centralised buttons. Hand sizes were considered so that the 5th to 95th percentiles would not have issues holding the Knuckles. Extra size customisations were included, as was a strap.
Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ. The drug had completed phase III clinical trials, however in May 2006 Bristol-Myers Squibb announced that it had discontinued further development. Data on muraglitazar is relatively sparse due to the brief introduction and subsequent abandonment of this agent. One double-blind randomized clinical trial comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (p <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. A meta-analysis of the phase II and III clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and congestive heart failure (CHF) when compared to placebo or pioglitazone.
On July 13, 2024, Trump survived an assassination attempt while addressing a campaign rally near Butler, Pennsylvania. Trump was shot at by Thomas Crooks, a 20-year-old man from Bethel Park, Pennsylvania, who fired eight rounds with an AR-15–style rifle from the roof of a building located approximately 400 feet (120 meters) from the stage. According to the FBI, Trump was hit by a bullet, and injured in his upper right ear. He raised a hand to his ear before dropping down on his podium behind the lectern for cover. Secret Service agents lunged toward Trump and shielded him. After the assailant was declared "down", agents helped Trump get up. Blood was visible on his ear and face. He asked the Secret Service agents to let him get his shoes. According to Trump, the agents "hit me so hard that my shoes fell off, and my shoes are tight." As of October 12, 2024, none of the medical records pertaining to his wounds had been released. In July 2024, psychologist Simon McCarthy-Jones of Trinity College Dublin said in The Conversation that "the potential effect of the attempted assassination of Trump upon Trump's mental health – whether negligible, negative or positive – cannot be ignored". McCarthy-Jones stated that Trump being an extrovert might improve his ability to deal with the psychological impact of the event.
Sources: en.wikipedia.org
=== Immigration enforcement and protests against ICE === In early June 2025 in response to street protests against ICE actions, President Trump activated and sent 2,100 members of the California National Guard to the Los Angeles area. Reuters reported that the protests were the strongest domestic backlash to Trump since he took office in January, and became a focal point in a national debate over immigration, protest, the use of federal force in domestic affairs, the boundaries of presidential power, and freedom of speech and assembly.
== Normal amount == In a urinalysis, the normal amount of urinary calcium can be measured in amount per time (commonly per 24 hours). It can also be measured in amount per mass of creatinine, which avails for estimating the urinary calcium excretion in a spot urine sample, because urinary creatinine clearance is relatively unaffected by differences in free water clearance which occurs, for example, in dehydration and which would distort the interpretation of the urinary calcium in a spot urine sample. Normally, in an average adult, the amount of calcium excreted in the urine is 100–250 mg over a 24-hour period. For those on low-calcium diets, there is normally 50–150 mg/24 hours, while those on a calcium-free diet will have 5–40 mg/24 hours. The following reference ranges are for persons with average calcium intake (600–800 mg/day for adults):
=== Separation methods === Initially, analytes in a metabolomic sample comprise a highly complex mixture. This complex mixture can be simplified prior to detection by separating some analytes from others. Separation achieves various goals: analytes which cannot be resolved by the detector may be separated in this step; in MS analysis, ion suppression is reduced; the retention time of the analyte serves as information regarding its identity. This separation step is not mandatory and is often omitted in NMR and "shotgun" based approaches such as shotgun lipidomics. Gas chromatography (GC), especially when interfaced with mass spectrometry (GC-MS), is a widely used separation technique for metabolomic analysis. GC offers very high chromatographic resolution, and can be used in conjunction with a flame ionization detector (GC/FID) or a mass spectrometer (GC-MS). The method is especially useful for identification and quantification of small and volatile molecules. However, a practical limitation of GC is the requirement of chemical derivatization for many biomolecules as only volatile chemicals can be analysed without derivatization. In cases where greater resolving power is required, two-dimensional chromatography (GCxGC) can be applied. High performance liquid chromatography (HPLC) has emerged as the most common separation technique for metabolomic analysis. With the advent of electrospray ionization, HPLC was coupled to MS.
==== Metabolism ==== Not many studies have been conducted on the biotransformation of bromazolam, mainly because this drug is relatively new. However, in a study of Wagmann et al. (2020), the biotransformation of bromazolam is studied in depth. The results of this study are described in the text below. Blood plasma and urine of two individuals suspected of taking bromazolam were analysed for bromazolam and its metabolites. Bromazolam was detected in all four of the samples. One of the urine samples contained 8 bromazolam metabolites these were: phenyl-hydroxy bromazolam, 4-hydroxy bromazolam, α-hydroxy bromazolam, α-4-dihydroxy bromazolam, bromazolam N-glucuronide, phenyl-hydroxy bromazolam glucuronide, α-hydroxy bromazolam glucuronide, and 4-hydroxy bromazolam glucuronide. In the blood plasma sample of the same individual only the three mono-hydroxylated metabolites were found. The urine of the other individual only contained two metabolites, which were also found in the other urine sample, and the blood plasma did not show any metabolite of bromazolam present in the body. A study where pooled human liver S9 fractions (pHLS9) were incubated with bromazolam was conducted. Seven, out of the eight urine, bromazolam metabolites were found in the pHLS9 samples. Phenyl-hydroxylated glucuronide bromazolam was not found in the pHLS9 samples. Several monooxygenases and glucuronosyltransferases have been screened, in vitro, for activity of the biotransformation of bromazolam.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.